Michael L. Blute Sr., MDProfessor of Urology, Harvard Medical School; Chief of Urology, Massachusetts General Hospital, Boston, Massachusetts
Dr. Michael L. Blute is currently Chief of the Department of Urology at The Massachusetts General Hospital and the Walter S. Kerr, Jr, Professor of Urology, Harvard Medical School. Previously Dr. Blute was the Anson L. Clark Professor and Chairman in the Department of Urology, Mayo Clinic, Rochester, Minnesota. He remained as Chairman of the Department of Urology and on the Executive Board of the Mayo Clinic until appointed Interim Chief of Urology and Director of the Cancer Center of Excellence at the University of Massachusetts Memorial Medical Center in 2010. In April 2012 Dr. Blute was appointed Chief of Urology at the Massachusetts General Hospital in Boston.
Dr. Blute has a major interest in urologic oncology and is well-known in the field of academic urology. His major areas of interest include prostate cancer, nephron-sparing surgery for kidney masses, and the management of complex renal cell and bladder neoplasms. He serves as a reviewer on 13 editorial boards; he also served on the AUA Renal Mass Guideline Panel and served on the American Joint Committee on Cancer. He is the recipient of the 2010 AUA Career Contribution Award and the Andrew C. Novick Lecturer and Contribution Award from the Kidney Cancer Association in 2012. His bibliography includes 368 peer-reviewed publications, one book, and 26 book chapters.
Recent Contributions to PracticeUpdate:
- Abdominal Wall Morbidity After Flank Incision for Open Partial Nephrectomy
- Sunitinib Is Noninferior to Sunitinib/Nephrectomy in Metastatic RCC
- Hypothermia During Partial Nephrectomy for Patients With Renal Tumors
- Robotic vs Laparoscopic vs Open Surgery Outcomes in Patients Undergoing Radical Nephrectomy
- Selective Arterial Embolization for Large or Symptomatic Renal Angiomyolipoma
- Partial vs Radical Nephrectomy and Subsequent Hypertension Risk After Renal Tumor Resection
- Outcomes of Robot-Assisted Partial Nephrectomy for Clinical T2 Renal Tumors
- Sunitinib Alone or After Nephrectomy in Renal Cell Carcinoma
- Comparative Survival Following Initial Cytoreductive Nephrectomy vs Initial Targeted Therapy for Metastatic RCC
- Radical Nephrectomy With or Without Lymph Node Dissection for High-Risk Nonmetastatic Renal Cell Carcinoma